Cite
Turkova A, White E, Mujuru HA, et al. Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children. N Engl J Med. 2021;385(27):2531-2543doi: 10.1056/NEJMoa2108793.
Turkova, A., White, E., Mujuru, H. A., Kekitiinwa, A. R., Kityo, C. M., Violari, A., Lugemwa, A., Cressey, T. R., Musoke, P., Variava, E., Cotton, M. F., Archary, M., Puthanakit, T., Behuhuma, O., Kobbe, R., Welch, S. B., Bwakura-Dangarembizi, M., Amuge, P., Kaudha, E., Barlow-Mosha, L., Makumbi, S., Ramsagar, N., Ngampiyaskul, C., Musoro, G., Atwine, L., Liberty, A., Musiime, V., Bbuye, D., Ahimbisibwe, G. M., Chalermpantmetagul, S., Ali, S., Sarfati, T., Wynne, B., Shakeshaft, C., Colbers, A., Klein, N., Bernays, S., Saïdi, Y., Coelho, A., Grossele, T., Compagnucci, A., Giaquinto, C., Rojo, P., Ford, D., Gibb, D. M. (2021). Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children. The New England journal of medicine, 385(27), 2531-2543. https://doi.org/10.1056/NEJMoa2108793
Turkova, Anna, et al. "Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children." The New England journal of medicine vol. 385,27 (2021): 2531-2543. doi: https://doi.org/10.1056/NEJMoa2108793
Turkova A, White E, Mujuru HA, Kekitiinwa AR, Kityo CM, Violari A, Lugemwa A, Cressey TR, Musoke P, Variava E, Cotton MF, Archary M, Puthanakit T, Behuhuma O, Kobbe R, Welch SB, Bwakura-Dangarembizi M, Amuge P, Kaudha E, Barlow-Mosha L, Makumbi S, Ramsagar N, Ngampiyaskul C, Musoro G, Atwine L, Liberty A, Musiime V, Bbuye D, Ahimbisibwe GM, Chalermpantmetagul S, Ali S, Sarfati T, Wynne B, Shakeshaft C, Colbers A, Klein N, Bernays S, Saïdi Y, Coelho A, Grossele T, Compagnucci A, Giaquinto C, Rojo P, Ford D, Gibb DM. Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children. N Engl J Med. 2021 Dec 30;385(27):2531-2543. doi: 10.1056/NEJMoa2108793. PMID: 34965338.
Copy
Download .nbib